Slim Wellness Center Review: What Its GLP-1 Documentation Does—and Does Not—Establish

Slim Wellness Center makes several questions easier to answer than a medication advertisement alone would: who conducts patient visits, where the clinic operates, what its advertised tirzepatide program costs, and which pharmacy it names. For adults comparing GLP-1 services, that is useful documentation. The harder question is what those disclosures prove. A named clinician and a monthly price describe a business and a proposed care arrangement; they do not establish the effectiveness of the particular preparation a patient will receive.

This review separates the clinic’s documented offerings from independent clinical and regulatory context. Public pages consulted October 19, 2026, describe a small, physician-supervised medical wellness clinic in National City, California, with semaglutide and tirzepatide programs and a California-only tirzepatide telehealth option. The strongest evidence concerns advertised access, responsibilities and prices. Important gaps remain around the exact dispensed product, remote delivery, billing terms and measured outcomes. Provider statements about professional credentials, pharmacy verification and certification are reported here as claims, not independently verified findings.

At a glance

Advertised tirzepatide price: $179/month in clinic or $200/month through telehealth, for California patients only; all prescribed dose levels, consultations and necessary supplies are advertised as included.
Sources: [5]
Treating professional: The clinic says nurse practitioner Lyan Love McCullough conducts consultations, treatment planning and follow-ups; Dr. Gidon Akler supervises clinical protocols.
Sources: [6]
Named pharmacy: The website identifies Integrity Compounding Pharmacy in Sandy Springs, Georgia, as its medication source. This review did not independently verify pharmacy credentials.
Sources: [11]
Compounded-drug disclosure: The clinic acknowledges that compounded preparations are not FDA approved and says the clinician will discuss their source when a treatment plan involves one.
Sources: [8]
Contract documentation gap: The consulted terms-of-service address displays a privacy policy, leaving renewal, cancellation and refund conditions unestablished.
Sources: [10]

Start with what the clinic can actually document

Slim Wellness Center advertises access to semaglutide and tirzepatide programs when clinically appropriate. Its physical service area includes National City, Chula Vista, Paradise Hills, Bonita, Imperial Beach and greater San Diego. The published tirzepatide offer also includes telehealth for California patients only. That makes this a documented GLP-1 service, rather than a wellness business whose connection to these medicines must be inferred. It does not establish nationwide access or guarantee that an applicant will receive a prescription.

The business is broader than weight-management medication. It advertises MIC + B12 injections, either alone or alongside a GLP-1 program; lab-based hormone replacement and testosterone replacement services; peptide protocols; custom intravenous drips; and NAD+ and B12 injections. Its aesthetic offerings include Emerald Laser and Exion skin tightening. These are separate advertised services, not evidence that adding them improves GLP-1 outcomes. The consulted material does not establish that they are included in the tirzepatide monthly price.

This distinction matters when evaluating a wellness clinic: the existence of a service is one question, its clinical support another. Slim’s public pages establish that the clinic markets these offerings and describes medical evaluation before treatment. They do not establish comparative effectiveness or patient outcomes across the menu. Our guide to what public provider documents can prove explains why a clear service description is useful without being equivalent to independent validation.

What the public documentation establishes
Topic	Documented statement	Remaining question
GLP-1 offerings	Semaglutide and tirzepatide programs are advertised.	Which exact product, formulation and route would be prescribed?
Tirzepatide price	$179/month in clinic or $200/month by telehealth, California only.	What quantity and supply period does each payment cover?
Care responsibility	A named nurse practitioner conducts patient visits and follow-ups.	What follow-up frequency and response time are promised?
Pharmacy	Integrity Compounding Pharmacy is named as the source.	What preparation and fulfillment arrangements apply to an individual prescription?
Commercial terms	The terms-of-service address displays a privacy policy.	What are the renewal, cancellation and refund rules?

Sources: [6] [5]

A named care team is informative, not independent credential verification

The clinic identifies Lyan Love McCullough as its nurse practitioner and says she handles consultations, treatment planning, dosing and follow-ups for every patient. It presents that arrangement as continuity with the same professional from the first visit onward. This is more specific than an unnamed “medical team,” and gives prospective patients a concrete person and role to ask about. A nurse practitioner is not necessarily a physician, and the site distinguishes her patient-facing responsibilities from those of its medical director.

According to the website, Dr. Gidon Akler sets and supervises clinical protocols, while Lyan conducts patient visits. The site attributes training in Pediatrics and Medical Genetics at Mount Sinai Hospital in New York to Dr. Akler and states that he is board certified in Medical Genetics and Genomic Medicine. Those are provider-reported credentials. The consulted material does not independently verify licenses, board status or the practical frequency of medical-director involvement in an individual patient’s treatment.

Enrollment begins with an advertised 60-second questionnaire covering goals and health history, followed by a medical evaluation. The minute-long description belongs to the questionnaire—not to the duration of the clinical assessment. The clinic says evaluation considers history, goals and laboratory testing when needed; qualification also depends on BMI and current medicines. It publishes no specific BMI threshold or mandatory GLP-1 laboratory protocol in the consulted material. Its privacy policy describes the services as intended for adults 18 and older.

Sources: [6] [5] [7]

The monthly price is clear; the complete purchase terms are not

Slim advertises tirzepatide at $179 per month in clinic or $200 per month through telehealth, for California patients only. It says all prescribed dose levels, consultations and necessary supplies are included; the in-clinic program additionally includes a 3D scan. The quoted offer is not described as an introductory discount in the consulted text. However, “month” does not establish an exact medication supply period, dispensed quantity or guaranteed future price, and the advertised offer does not unambiguously identify the formulation, presentation or route.

For other medicines, the clinic says it will explain exact pricing before a patient commits. Consequently, the tirzepatide rate should not be applied to semaglutide or to the broader wellness menu. Laboratory charges and possible items outside the explicit inclusions are not resolved. Nor does the documentation establish accepted insurance plans, medication coverage or prior-authorization assistance. Those are distinct questions: an advertised cash price does not answer whether a particular health plan covers a visit or prescription.

The clinic partners with Cherry and accepts CareCredit to divide treatment costs into monthly payments. Applications take place directly with those companies under their own privacy policies; the material does not establish approval or financing terms for an individual applicant. Separately, the terms-of-service address displays a privacy policy rather than commercial conditions. Automatic billing, minimum commitments, cancellation deadlines and refunds therefore remain unestablished. A prospective patient should request those terms in writing rather than treating the monthly price as a complete contract.

Sources: [5] [6] [7] [10]

The pharmacy disclosure leaves product-level questions open

Slim names Integrity Compounding Pharmacy as its medication source and publishes an address of 8601 Dunwoody Place, Suite 750, Sandy Springs, Georgia 30350, with telephone number 404-815-1610. The website also calls the pharmacy “verified” and describes Slim as a LegitScript-approved provider. Naming the pharmacy creates a useful contact path and identifies an organization to ask about dispensing. Neither the label nor the certification statement was independently verified for this review, and neither establishes the performance of a particular preparation.

The clinic says compounded medicines are prescribed at a licensed provider’s discretion when clinically appropriate, after medical evaluation. It also says the treating professional will explain a compounded preparation’s source and implications. However, the pages do not unambiguously identify the exact brand, formulation, presentation or route for every advertised GLP-1 program. General references to injections do not resolve all of those questions. A patient therefore needs a product-specific explanation, not simply confirmation that the clinic offers “tirzepatide” or “semaglutide.”

FDA states that compounded preparations are not FDA approved and do not undergo its premarket review for safety, effectiveness and quality. Nonapproval alone does not demonstrate clinical inequivalence, but it also does not establish equivalence to an approved product. FDA recommends compounded drugs for patients whose medical needs cannot be met by an FDA-approved drug, with a prescription and a state-licensed pharmacy. Our explanation of approved medicines and compounded preparations separates those regulatory and evidence questions.

Sources: [11] [5] [8] [1]

Clinical trials support narrower conclusions than clinic marketing

Independent trials can explain why these medicines are considered for weight management, but they cannot establish Slim’s performance. STEP 1 studied 1,961 adults with obesity, or overweight plus a weight-related condition, without diabetes, over 68 weeks. With lifestyle intervention in both groups, mean weight change was −14.9% for the studied subcutaneous semaglutide 2.4 mg weekly arm versus −2.4% for placebo. That dose identifies the research arm, not instructions for a patient. Novo Nordisk funded the trial.

In STEP 1, discontinuation because of gastrointestinal events occurred in 4.5% of semaglutide participants versus 0.8% of placebo participants. The result therefore includes a tolerability context, not just an average weight change. It is not a measured outcome for Slim, its compounded preparations, another route or an individual patient. The STEP 1 evidence guide explains how population, duration and treatment details constrain the conclusions readers can reasonably draw from the headline percentage.

The clinic’s public service descriptions do not supply a measured patient-outcome dataset with a defined population, follow-up duration and accounting for people who discontinue treatment. Its advertised follow-ups and nutrition guidance describe intended support, not proof of sustained results. Nor should results from separate semaglutide and tirzepatide trials be treated as a head-to-head ranking of Slim’s programs. The key distinction is between evidence for a studied treatment and evidence that a particular clinic reproduces that treatment or its outcomes.

Sources: [3] [4] [11]

Follow-up is described, but the remote pathway needs clarification

Slim describes an initial evaluation followed by periodic check-ins and injections depending on the program, with a personalized schedule. It also advertises aftercare, nutrition guidance and ongoing follow-ups. Together with the named nurse practitioner, those statements outline a continuing care relationship rather than a one-time questionnaire purchase. They do not establish a fixed visit frequency, a specific nutrition-service format or a clinical response-time commitment. Asking what happens between scheduled visits would make the advertised support more concrete.

The California-only telehealth tirzepatide offer is explicit, but the complete remote pathway is not. Other site language emphasizes starting treatment in clinic and distinguishes the business from telehealth applications. The consulted documentation does not fully reconcile those descriptions or explain whether any in-person step applies to a remote patient. It also leaves shipping charges, preparation time, dispatch, arrival, refrigeration arrangements and possible pickup unresolved. A monthly telehealth price should not be interpreted as a documented delivery promise.

Those omissions are especially relevant if the prescribed preparation is injectable. FDA advises not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy to resolve the concern. That is general regulatory guidance, not evidence of a delivery problem at Slim. Before enrollment, patients can ask who handles a compromised shipment, which number to call and what replacement process applies. Our delivery-evidence guide explains why dispatch and arrival are different commitments.

Sources: [5] [11] [6] [1]

Safety disclosures are a starting point for discussion

Slim’s safety page lists exclusions involving personal or family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia syndrome type 2, a serious allergic reaction to semaglutide, tirzepatide or an ingredient, and pregnancy, planned pregnancy or breastfeeding. These are the clinic’s published screening boundaries, not an individualized eligibility determination. The website also says treatment is not suitable for everyone. Completing the short questionnaire or meeting a general weight-related criterion therefore should not be mistaken for approval to begin treatment.

NIDDK describes medication selection as a discussion of benefits, side effects, existing conditions, other medicines, family history and cost. It also emphasizes that medication accompanies healthy eating and physical activity, and that follow-up concerns response and tolerability. For Slim, a useful question is how those topics are revisited after the initial evaluation. The clinic’s promise of check-ins is relevant, but the public description does not establish exactly what is assessed or how a patient reports a concern between appointments.

For non-emergency treatment questions, Slim directs patients to call (619) 765-4141 during business hours. That is a documented support route, not a promise of round-the-clock clinical access. FDA has received reports of errors measuring or administering compounded medicines, including some associated with hospitalization. Patients should clarify product-specific instructions with the prescriber or pharmacist rather than calculate doses from a review. Those reports do not provide a provider-specific event rate and should not be presented as evidence of an incident at Slim.

Sources: [8] [5] [2] [1]

Practical access and privacy details worth checking before enrollment

The clinic lists its address as 655 Euclid Avenue, Suite 210, National City, California 91950. Its contact page gives Monday–Friday hours of 9 a.m.–6 p.m., with Saturday and Sunday closed, and says free parking is available near the entrance in a fully accessible building. No referral is required to request an appointment. Patients can begin with the online questionnaire or call (619) 765-4141; the contact page also offers text and email contact through the front desk.

The privacy policy distinguishes general website information from patient medical records and treatment information. It says those clinical records are covered by a separate Notice of Privacy Practices provided when someone becomes a patient. The policy also warns against sending sensitive medical details through unsecured email or website forms and acknowledges that absolute security cannot be guaranteed. The existence of an email contact option should therefore not be read as an invitation to send a detailed medical history through ordinary email.

For text messages, the policy permits opting out by replying STOP and says marketing-text consent is not a condition of treatment. It distinguishes marketing opt-outs from transactional messages connected with active care. These are useful communication disclosures, but they do not establish a secure patient portal, Spanish-language services or a promised clinical reply time. Before sharing records, patients can ask which channel is appropriate for medical information and obtain the separate clinical privacy notice alongside the missing commercial terms.

Sources: [6] [9] [7]

Questions & answers

Does Slim Wellness Center offer both semaglutide and tirzepatide?

Yes. It advertises both programs when clinically appropriate, following medical evaluation. The public monthly price is for tirzepatide, not semaglutide. Ask for the exact prescribed product, formulation, route and presentation, because the program names alone do not resolve those details. Enrollment is not a guarantee of a prescription.

Sources: [5]

What is included in the $179 or $200 tirzepatide offer?

The clinic advertises $179/month in clinic or $200/month through telehealth, for California patients only. All prescribed dose levels, consultations and necessary supplies are included, with a 3D scan added in clinic. The documentation does not establish dispensed quantity, an exact supply period, laboratory charges or complete renewal and cancellation terms.

Sources: [5] [10]

Will visits be with the medical director?

The website says patient visits are conducted by nurse practitioner Lyan Love McCullough, who also handles treatment planning and follow-ups. It describes Dr. Gidon Akler as the medical director responsible for setting and supervising protocols. Physician supervision should not be interpreted as a promise that the physician personally conducts each consultation.

Sources: [6]

Can someone outside California use its telehealth program?

The published tirzepatide offer is expressly limited to California patients. The consulted material does not establish access for patients elsewhere. Even within California, prospective remote patients should confirm whether an in-person step is required and how prescriptions are fulfilled, because the website does not fully explain the remote care and delivery process.

Sources: [5] [6]

Does naming Integrity Compounding Pharmacy establish FDA approval?

No. FDA approval applies to a specific product, not a clinic or pharmacy. Slim itself acknowledges that compounded preparations are not FDA approved. Naming Integrity makes the stated source identifiable, but does not establish approval, equivalence to an approved medicine or independently verified pharmacy credentials. Ask which exact preparation would be dispensed.

Sources: [11] [8] [1]

What should I obtain before paying or applying for financing?

Request an itemized treatment quote, the quantity and supply period covered, any laboratory or delivery charges, follow-up arrangements, and written renewal, cancellation and refund rules. Slim says it explains other medication prices before commitment and offers Cherry and CareCredit, but the consulted terms address does not provide commercial conditions. Financing approval and repayment terms require separate confirmation.

Sources: [5] [6] [10] [7]

Our assessment

Slim Wellness Center provides useful public detail about its treating professional, medical-director role, California access, tirzepatide pricing and named pharmacy. Its explicit acknowledgment of compounded-drug limitations is also material. These disclosures make the service more understandable, but do not independently validate credentials, establish product equivalence or demonstrate clinic-specific outcomes. The largest unresolved questions are practical and product-specific: what exactly is dispensed, how remote care and fulfillment work, and what financial obligations apply after enrollment. For a prospective patient, the next step is a written product and service explanation—not an assumption that trial averages, certification claims or an inclusive monthly price answer those questions.

Visit Slim Wellness Center’s official site ↗

This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.

Sources & documentation

Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.

Slim Wellness Center Review: What Its GLP-1 Documentation Does—and Does Not—Establish

At a glance

01Start with what the clinic can actually document

02A named care team is informative, not independent credential verification

03The monthly price is clear; the complete purchase terms are not

04The pharmacy disclosure leaves product-level questions open

05Clinical trials support narrower conclusions than clinic marketing

06Follow-up is described, but the remote pathway needs clarification

07Safety disclosures are a starting point for discussion

08Practical access and privacy details worth checking before enrollment